fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.

Alitretinoin

2 Limited Use · 2 not a benefit

Hanzema · DIN 02477432 · 10 mg · capsule

Limited Use, Reason for Use code 442 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 442 required
Write on scriptReason for Use code 442 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Hanzema · DIN 02477432 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-06-09 · brand HANZEMA · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 10 MG · company Dr. reddy's laboratories inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Hanzema: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9868). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477432)

Source record
DIN 02477432: Hanzema Raw flags: sec12=Y, sec3=Y Item: 843600092; group id 856; item number 2076; lccId 00234; manufacturer id DRR Source form: Cap; strength: 10mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $16.9868; ministry $16.9868 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477432 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96841
Interchangeable products
Toctino · DIN 02337630 · not recorded
Shortage status: resolved shortage (ended June 28, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477432
Shortage record checked October 6, 2026

Hanzema · DIN 02477440 · 30 mg · capsule

Limited Use, Reason for Use code 442 requiredMarketed · checked October 5, 2026
StatusLimited Use, Reason for Use code 442 required
Write on scriptReason for Use code 442 (criteria below)
Patient paysIf the Reason for Use code is written and the criteria are met, ODB 65 and over pays: • ODB senior: $100/program-year deductible • Then up to $6.11 per prescription • Or, if enrolled in the Seniors Co-Payment Program (income-tested; individual net income below $25,480 for Aug 2026–Jul 2027): no deductible, up to $2 per prescription If the criteria are not met, ODB does not pay this product under Limited Use. [Limited Use benefit, Formulary flag]
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Hanzema · DIN 02477440 Manufacturer: Dr. Reddy's Laboratories Inc.; listing date 2021-07-30 Health Canada: Marketed since 2021-06-09 · brand HANZEMA · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 30 MG · company Dr. reddy's laboratories inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Hanzema: Formulary list price $16.99 per unit (the source does not state the unit; exact figure $16.9868). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02477440)

Source record
DIN 02477440: Hanzema Raw flags: sec12=Y, sec3=Y Item: 843600093; group id 856; item number 2077; lccId 00234; manufacturer id DRR Source form: Cap; strength: 30mg Recorded listing: Limited Use: paid only with a Reason for Use code and the criteria below Source prices (unrounded): $16.9868; ministry $16.9868 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02477440 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=96842
Interchangeable products
Toctino · DIN 02337649 · not recorded
Shortage status: resolved shortage (ended April 15, 2022); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02477440
Shortage record checked October 6, 2026

Toctino · DIN 02337630 · 10 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.Discontinued July 14, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Toctino · DIN 02337630 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2013-04-30 Health Canada: Cancelled post market since 2023-07-14 · brand TOCTINO · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 10 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Toctino: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337630)

Source record
DIN 02337630: Toctino Raw flags: notABenefit=Y, sec3=Y Item: 843600092; group id 856; item number 2076; lccId 00234; manufacturer id GSK Source form: Cap; strength: 10mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337630 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82321
Interchangeable products
Hanzema · DIN 02477432 · $16.9868
Shortage status: discontinued (June 30, 2023, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337630
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 14, 2023 — choose a marketed DIN from the same-category list.

Toctino · DIN 02337649 · 30 mg · capsule

Listed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.Discontinued July 14, 2023 · checked October 5, 2026
StatusListed, not a benefit; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Write on scriptnot a benefit; no Exceptional Access criteria on record (an EAP request with clinical rationale is still possible); see alternatives; Health Canada lists this DIN as Cancelled post market since 2023-07-14 — choose a marketed DIN from the same-category list.
Patient paysNot paid by ODB 65 and over; see alternatives
Ontario Limited Use criteria, code 442
Reason for Use code 442 For adult patients with severe (see note 1 below) chronic (see note 2 below) hand eczema AND unresponsive to an 8 week course of high potency topical corticosteroids. 1. Severe defined based on the Physician Global Assessment (PGA), including: - At least one of the following cardinal features present at baseline as moderate or severe: erythema, scaling, hyperkeratosis/lichenification; and - one of the following features present as severe: vesiculation, edema, fissures, pruritus/pain; and - with an area of greater than 30% of affected hand surface 2. Chronic defined as: - persists for greater than 3 months; OR - reoccurs greater than or equal to 2 times within 12 months Coverage limit: LU Authorization Period: 1 year
1 brand, same coverage
Toctino · DIN 02337649 Manufacturer: GlaxoSmithKline Inc., GlaxoSmithKline Consumer Health Care; listing date 2013-04-30 Health Canada: Cancelled post market since 2023-07-14 · brand TOCTINO · ATC D11AH04 ALITRETINOIN · form Capsule · route Oral · ingredients ALITRETINOIN 30 MG · company Glaxosmithkline inc · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Toctino: Formulary list price None per unit (the source does not state the unit; exact figure not recorded). What the ministry pays, not the patient.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02337649)

Source record
DIN 02337649: Toctino Raw flags: notABenefit=Y, sec3=Y Item: 843600093; group id 856; item number 2077; lccId 00234; manufacturer id GSK Source form: Cap; strength: 30mg Recorded listing: Listed, not a benefit; ODB pays only for the benefit products in this interchangeable category Source prices (unrounded): not recorded; ministry not recorded Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02337649 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=82322
Interchangeable products
Hanzema · DIN 02477440 · $16.9868
Shortage status: discontinued (June 30, 2023, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337649
Shortage record checked October 6, 2026
Health Canada lists this DIN as Cancelled post market since July 14, 2023 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (D11AH): coverage varies; not interchangeable

  • Pimecrolimus (Elidel): limited Use 383
Other drugs in the same formulary class (84:36 Miscellaneous Skin and Mucous Membrane Agents) and how they are covered

Matched class: 84:36 Miscellaneous Skin and Mucous Membrane Agents

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Public program routes: ODB 65 and over Covered without a code on the Ontario formulary: ACITRETIN, AZELAIC ACID, FLUOROURACIL, ISOTRETINOIN, ZINC SULFATE Some products covered without a code (check the product listing): COLLAGENASE 84:36 Miscellaneous Skin and Mucous Membrane Agents

PIMECROLIMUS

· 1 products · Limited Use, codes 383 · strengths: 1% · Cr

ACITRETIN

· 6 products · General benefit · strengths: 10mg, 25mg · Cap

AZELAIC ACID

· 1 products · General benefit · strengths: 15% · Top Gel

COLLAGENASE

· 2 products · General benefit (1), Temporary benefit (1) · strengths: 250Unit/g · 30g Pk, Oint-30g Pk

FLUOROURACIL

· 1 products · General benefit · strengths: 5% · Cr

ISOTRETINOIN

· 8 products · General benefit · strengths: 10mg, 20mg, 30mg, 40mg · Cap

ZINC SULFATE

· 2 products · General benefit · strengths: 0.5%, 10mg · Oint, Sup

BRODALUMAB

· 1 products · Limited Use, codes 553 · strengths: 210mg/1.5mL · Inj Sol-Pref Syr

CALCIPOTRIOL

· 1 products · Limited Use, codes 191 · strengths: 50mcg/g · Oint

CALCITRIOL

· 1 products · Limited Use, codes 191 · strengths: 3mcg/g · Oint

IXEKIZUMAB

· 2 products · Limited Use, codes 526 · strengths: 80mg/mL · Inj Sol-Pref Autoinj, Inj Sol-Pref Syr

RISANKIZUMAB

· 3 products · Limited Use, codes 574 · strengths: 75mg/0.83mL, 150mg/mL · Inj Sol-0.83mL Pref Syr (Preservative-Free), Inj Sol-Pref Pen (Preservative-Free), Inj Sol-Pref Syr (Preservative-Free) Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 84:36 and 3 more
Full class listing Related classes: 84:04 Anti-Infectives, 84:06 Anti-Inflammatory, 84:28 Keratolytic Agents Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE HANZEMA (alitretinoin) is indicated for the treatment of severe chronic hand eczema refractory to high potency topical corticosteroids in adults. HANZEMA should only be prescribed by physicians knowledgeable in the use and monitoring requirements of systemic retinoids, who understand the risk of teratogenicity in females of child bearing potential (see CONTRAINDICATIONS and WARNINGS AND PRECAUTIONS: Serious Warnings and Precautions and Special Populations, Women of Child Bearing Potential). Geriatrics (> 65 years of age): Clinical trial experience has not identified differences in responses between elderly and other patients. However clinical studies of alitretinoin did not include sufficient numbers of subjects aged 65 years and over to determine with certainty whether they respond differently from younger subjects (ACTION AND CLINICAL PHARMACOLOGY, Special Populations and Conditions, Pharmacokinetics in special populations). HANZEMA Page 3 of 40 Pediatrics (< 18 years of age): HANZEMA is not recommended for use in patients under 18 years of age. https://pdf.hres.ca/dpd_pm/00067982.PDF PM date: October 20, 2022 Source product: HANZEMA; DIN 02477432; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.

Availability

Toctino · DIN 02337630 Shortage status: discontinued (2023-06-30, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337630

Check this DIN again

Toctino · DIN 02337649 Shortage status: discontinued (2023-06-30, reported by GLAXOSMITHKLINE INC); reports as of October 6, 2026 (Health Product Shortages Canada) Source: https://healthproductshortages.ca/search?term=02337649

Check this DIN again
Program rules and quotes
Public program routes (Ontario context; residency, health-card/OHIP requirements and enrolment must be confirmed from the quoted rules): ODB 65 and over (seniors path) Eligibility: You may qualify for the Ontario Drug Benefit (ODB) program when you turn 65 years old. (ontario.ca, August 18, 2026 ↗) Eligibility: The Ontario Drug Benefit program is for Ontario residents only and prescriptions must be filled in an Ontario pharmacy to be covered. (ontario.ca, August 18, 2026 ↗) Eligibility: Individual annual net income threshold Program year August 1, 2026 to July 31, 2027: $25,480 This applies to a senior who: does not have a spouse has a married spouse with whom they no longer live in a conjugal relationship has a spouse living in a long-term care home or community home for opportunity (ontario.ca, July 2, 2026 ↗) Eligibility: Combined annual net income requirement Program year August 1, 2026 to July 31, 2027: $42,290 This applies to a senior who has a spouse, other than a spouse described. (ontario.ca, July 2, 2026 ↗) Eligibility: See the first-year deductible table. (ontario.ca, August 18, 2026 ↗) What it pays / costs: the first $100 of total prescription costs each program year (August 1 to July 31 the following year) (ontario.ca, August 18, 2026 ↗) What it pays / costs: up to $6.11 for each prescription filled or refilled (after paying the deductible) (ontario.ca, August 18, 2026 ↗) What it pays / costs: Seniors enrolled in the Seniors Co-Payment Program have no annual deductible and a reduced co-payment of up to $2. (ontario.ca, August 18, 2026 ↗) Enrolment: "We will send you a letter about 3 months before your 65th birthday to let you know you will automatically join the Ontario Drug Benefit program on the first day of the month after you turn 65 years old." (ontario.ca, August 18, 2026 ↗) Enrolment: "To enroll in the Seniors Co-Payment Program, a senior must submit an application to that program and qualify under certain income eligibility thresholds." (ontario.ca, August 18, 2026 ↗)
First year on ODB? The deductible depends on birth month
For your first year of Ontario Drug Benefit program eligibility, depending on the month you turn 65, the deductible may be lower than $100. That’s because the amount of the deductible is based on the number of months between your official start date (the first day of the month after you turn 65) and July 31 (the last day of the Ontario Drug Benefit program year). For example, if you turned 65 on April 15, your official start date would be May 1. Counting from May 1 to July 31 your deductible for the first year would be $25. Use this chart below to see what the deductible will be in your first year:
Month you were bornAmount of first-year deductible
July$100.00
August$91.67
September$83.33
October$75.00
November$66.67
December$58.33
January$50.00
February$41.67
March$33.33
April$25.00
May$16.67
June$8.33

Ontario source · 2026-08-18

Other review policies

For Toctino: no applicable EAP criteria are held and no ODB benefit is established. These policies do not establish coverage.

For rare, immediately life-, limb- or organ-threatening circumstances, the Compassionate Review Policy may consider an unfunded drug or indication, subject to its criteria and without bypassing the drug review process. Compassionate Review Policy

Compassionate Review Policy: source quote
Where there are rare clinical circumstances in immediately life, limb, or organ-threatening conditions, the Executive Officer will also consider requests for drugs or indications in situations where there has not been a decision by the Executive Officer to provide funding of the drug or indication as part of the Ontario Drug Benefit program (and the EAP), and the drug or indication requested would not circumvent the established review process for new drugs or indications as part of the drug submission process for listing within the Ontario Drug Benefit program. Requests must meet the criteria for the Compassionate Review Policy.

Ontario source; updated September 15, 2026

For cancer drugs, Case-by-Case Review considers rare, immediately life-threatening circumstances when no satisfactory funded treatment exists; its criteria and application process apply. Case-by-Case Review (cancer drugs)

Case-by-Case Review (cancer drugs): source quote
Note: Requests for cancer drugs are considered under the Case-by-Case Review Program (CBCRP) which is administered by Ontario Health (Cancer Care Ontario) on behalf of the Ministry of Health. The CBCRP considers funding requests for drugs (both oral therapies and injectable drugs) for the treatment of cancer in patients who have a rare clinical circumstance that is immediately life-threatening (death is likely within a matter of months) and who require treatment with an unfunded drug, because there is no other satisfactory and funded treatment. Please refer to the Ontario Health website for information on the application process, FAQs, eligibility criteria and program policies.

Ontario source; updated September 15, 2026